Federal contract award
75A50122C00081
VIR BIOTECHNOLOGY - OTA FOR PRE-EXPOSURE PROPHYLACTIC MONOCLONAL ANTIBODIES FOR THE PREVENTION OF INFLUENZA ILLNESS AND MEDICAL COUNTERMEASURES FOR OTHER EMERGING PATHOGENS OF PANDEMIC POTENTIAL
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST SHARING |
| Obligations | $65.9M |
| Current contract value | $65.9M |
| Potential contract value / ceiling | $65.9M |
| Start date | Sep 30, 2022 |
| Current end date | Dec 31, 2024 |
| Potential end date | Dec 31, 2024 |
| Latest award activity | Aug 5, 2025 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 5, 2025 | P00004 | $-8.4M | VIR BIOTECHNOLOGY - OTA FOR PRE-EXPOSURE PROPHYLACTIC MONOCLONAL ANTIBODIES FOR THE PREVENTION OF INFLUENZA ILLNESS AND MEDICAL COUNTERMEASURES FOR OTHER EMERGING PATHOGENS OF PANDEMIC POTENTIAL |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.